B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027
B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027
Summary
Non-Hodgkin’s lymphoma (NHL) comprises a heterogeneous group of proliferative malignancies that arise in the B cells, T cells, or natural killer (NK) cells within the lymphoid tissue, such as the lymph nodes, bone marrow, thymus, and spleen. B-cell lymphomas comprise approximately 85% of all NHL cases diagnosed in the US, and are a diverse group of blood cancers that arise in the B-cells. This report focuses on the four NHL subtypes that represent the greatest commercial opportunities for drug developers during the forecast period: Diffuse large B-cell lymphoma (DLBCL), Follicular lymphoma (FL), Marginal zone lymphoma (MZL) and Mantle cell lymphoma (MCL).
The B-Cell Non-Hodgkin’s lymphoma (NHL) market is expected to grow from $5.7bn in 2017 to $9.2bn by 2027 across the seven major markets (7MM - US, France, Germany, Italy, Spain, UK and Japan) at a compound annual growth rate (CAGR) of 4.9%. The main driver of the growth will be the rise of Chimeric Antigen Receptor (CAR) T cell therapies.
CAR-T therapies, including the currently marketed Yescarta and Kymriah and the pipeline agent lisocabtagene maraleucel, are expected to result in significant revenues due to premium pricing and clinical benefit in heavily pre-treated patients. Their combined revenues are expected to reach around $2.4bn in 2027.
CAR-T therapies have been highly anticipated in NHL, and they are expected to improve treatment outcomes in heavily-treated patients, an area of major unmet need. While currently only approved for the DLBCL subtype, CAR-T therapies are expected to expand into FL, MZL and MCL, and earlier lines of therapy between 2017 and 2027.
Increasing prevalence, primarily by aging populations and the approval and launch of new branded therapies: lisocabtagene maraleucel, ublituximab with umbralisib, Blincyto, tafasitamab, Venclexta, and enzastaurin will also drive market growth. Additionally, label expansion of currently marketed therapies: Yescarta, Kymriah, Polivy, Revlimid, Calquence, Aliqopa and Imbruvica will further drive growth during the forecast period.
A major barrier for market growth in B-cell NHL, however, will be the increased use of biosimilars and generics, in particular biosimilar rituximab. The branded Rituxan alone brought in around $2.5bn in the US in 2018.
Unmet needs remain in B-cell NHL, which will provide opportunities for developers, including the need for predictive and prognostic biomarkers, better therapies for relapsed or refractory DLBCL, further options in FL for specific patient subsets, and therapies for MCL patients refractory to and relapsed after treatment with Imbruvica.
The report “B-Cell Non-Hodgkin’s Lymphoma (NHL): Opportunity Analysis and Forecasts to 2027” provides an overview of B-cell NHL (FL, MZL, DLBCL and MCL), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management. Furthermore, it also provides annualized CLL therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven geographic regions, forecast from 2017 to 2027.
Key topics covered in the report include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the B-cell NHL therapeutics market.
Key Questions Answered:
- Which pipeline agents are the most promising and expected to launch in the 7MM? What are the forecasted sales of these agents and what will be their impact in the B-cell NHL market?
- What are the main unmet needs in B-cell NHL , which pipeline drugs will fulfill these needs, and to what extent?
- What are the current research and development (R&D) strategies being explored and how can developers incorporate these methods into their business strategy?
- Key Opinions Leaders (KOLs) insights across the 7MM, relating to the current treatment options and opinions on the late and early stage pipeline agents.
- Overview of B-cell NHL (FL, MZL, DLBCL and MCL), including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized CLL therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in seven geographic regions, forecast from 2017 to 2027. Forecast model includes previously diagnosed and newly diagnosed patients.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the B-cell NHL therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for B-cell NHL . The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global B-cell NHL market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global B-cell NHL market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global B-cell NHL market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- 1 Table of Contents
- 1.1 List of Tables
- 1.2 List of Figures
- 2 B-Cell NHL: Executive Summary
- 2.1 The B-Cell NHL Market Is Expected to Grow to $9.2B in 2027
- 2.2 Combinations with Rituxan and Label Expansions Across B-Cell NHL Will Continue to Be the Prominent Strategies Utilized by Developers
- 2.3 Moderate Level of Overall Unmet Need, but Opportunities Remain in Specific Settings
- 2.4 Large Pipeline Composed of Therapies with Relatively High Potential
- 2.5 What Do Physicians Think?
- 3 Introduction
- 3.1 Catalyst
- 3.2 Related Reports
- 3.3 Upcoming Related Reports
- 4 Disease Overview
- 4.1 Etiology
- 4.1.1 FL
- 4.1.2 MZL
- 4.1.3 DLBCL
- 4.1.4 MCL
- 4.2 Pathophysiology
- 4.2.1 FL
- 4.2.2 MZL
- 4.2.3 DLBCL
- 4.2.4 MCL
- 4.3 Staging
- 5 Epidemiology
- 5.1 Disease Background
- 5.2 Risk Factors and Comorbidities
- 5.3 Global and Historical Trends
- 5.3.1 US
- 5.3.2 5EU
- 5.3.3 Japan
- 5.4 Forecast Methodology
- 5.4.1 Sources
- 5.4.2 Forecast Assumptions and Methods
- 5.5 Epidemiological Forecast for B-Cell NHL (2017-2027)
- 5.5.1 Diagnosed Incident Cases of B-Cell NHL
- 5.5.2 Age-Specific Diagnosed Incident Cases of B-Cell NHL
- 5.5.3 Sex-Specific Diagnosed Incident Cases of B-Cell NHL
- 5.5.4 Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL
- 5.5.5 Diagnosed Incident Cases of DLBCL by Cancer Staging
- 5.5.6 Diagnosed Incident Cases of FL by Cancer Staging
- 5.5.7 Diagnosed Incident Cases of MZL by Cancer Staging
- 5.5.8 Diagnosed Incident Cases of MCL by Cancer Staging
- 5.5.9 Diagnosed Incident Cases of FL by Grade
- 5.5.10 Diagnosed Prevalent Cases of B-Cell NHL
- 5.5.11 Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL
- 5.6 Discussion
- 5.6.1 Epidemiological Forecast Insight
- 5.6.2 Limitations of the Analysis
- 5.6.3 Strengths of the Analysis
- 6 Current Treatment Options
- 6.1 Overview
- 6.1.1 Agents Used Across the Four Subtypes and Across Lines of Therapy
- 6.1.2 Rituxan Hycela, Rituximab Biosimilars, and Gazyva
- 6.1.3 Small Molecule Inhibitors in MCL, FL, and MZL
- 6.1.4 CAR-T Therapy in DLBCL
- 7 Unmet Needs and Opportunity Assessment
- 7.1 Overview
- 7.2 Predictive and Prognostic Molecular Biomarkers
- 7.2.1 GCB and Non-GCB Histology in DLBCL
- 7.2.2 Patients Who Are Not Cured with 1L R-CHOP in DLBCL
- 7.2.3 The POD24 Group in FL
- 7.2.4 DGM1-Positive Patients in DLBCL
- 7.3 Improvement of Cure Rate and Better Therapies for DLBCL Patients Who Are Not Cured by 1L R-CHOP
- 7.4 Further Options in FL for Various Patient Subsets
- 7.5 Patients Refractory to/Relapsed after Treatment with Imbruvica in MCL
- 7.6 Clinical Research in MZL
- 8 R&D Strategies
- 8.1 Overview
- 8.1.1 Label Expansions to Additional NHL Subtypes and Lines of Therapy
- 8.1.2 Novel Mechanisms of Action
- 8.1.3 Exploration of Novel Combinations With and Without Rituxan
- 8.2 Clinical Trials Design
- 8.2.1 Ongoing Late-Stage Trials of Marketed and Pipeline Drugs
- 8.2.2 PFS is the Most Common Clinical Trial Endpoint
- 8.2.3 Comparator Arms
- 9 Pipeline Assessment
- 10 Pipeline Valuation Analysis
- 10.1 Clinical Benchmark of Key Pipeline and Marketed Drugs
- 10.1.1 iNHL
- 10.1.2 DLBCL
- 10.1.3 MCL
- 10.2 Commercial Benchmark of Key Pipeline Drugs
- 10.2.1 iNHL
- 10.2.2 DLBCL
- 10.2.3 MCL
- 10.3 Competitive Assessment
- 10.4 Top-Line 10-Year Forecast
- 10.4.1 US
- 10.4.2 5EU
- 10.4.3 Japan
- 11 Appendix
- 11.1 Bibliography
- 11.2 Abbreviations
- 11.3 Methodology
- 11.3.1 Forecasting Methodology
- 11.3.2 Diagnosed Patients
- 11.3.3 Percent Drug-Treated Patients
- 11.3.4 Drugs Included in Each Therapeutic Class
- 11.3.5 Launch and Patent Expiry Dates
- 11.3.6 General Pricing Assumptions
- 11.3.7 Individual Drug Assumptions
- 11.3.8 Generic Erosion
- 11.3.9 Pricing of Pipeline Agents
- 11.4 Primary Research - KOLs Interviewed for This Report
- 11.5 Primary Research - Prescriber Survey
- 11.6 About the Authors
- 11.6.1 Analyst
- 11.6.2 Therapy Area Directors
- 11.6.3 Epidemiologist
- 11.6.4 Managing Epidemiologist
- 11.6.5 Global Director of Therapy Analysis and Epidemiology
- 11.6.6 Global Head and EVP of Healthcare Operations and Strategy
- 11.7 About GlobalData
- 11.8 Contact Us
- 11.9 Disclaimer
- List of Tables
- Table 1: B-Cell NHL: Key Metrics in the 7MM
- Table 2: Molecular Characteristics of NHL (2008 WHO Classification)
- Table 3: The Ann Arbor Staging System and the Cotswold Modifications for NHL
- Table 4: B-Cell NHL Cancer Stages
- Table 5: Risk Factors and Comorbidities for NHL
- Table 6: Treatment Guidelines for B-Cell NHL
- Table 7: Leading Treatments for B-Cell NHL
- Table 8: Ongoing Phase III/Pivotal Phase II Trials in B-cell NHL of Pipeline Drugs
- Table 9: Ongoing Phase III Trials in B-cell NHL of Marketed Drugs
- Table 10: Comparison of Therapeutic Classes in Development for NHL, 2018-2027
- Table 11: Clinical Benchmark of Key Pipeline and Marketed Drugs - iNHL
- Table 12: Clinical Benchmark of Key Pipeline and Marketed Drugs - DLBCL
- Table 13: Clinical Benchmark of Key Pipeline and Marketed Drugs - MCL
- Table 14: Commercial Benchmark of Key Pipeline and Marketed Drugs - iNHL
- Table 15: Commercial Benchmark of Key Pipeline and Marketed Drugs - DLBCL
- Table 16: Commercial Benchmark of Key Pipeline and Marketed Drugs - MCL
- Table 17: Key Events Impacting Sales for B-cell NHL, 2017-2027
- Table 18: B-cell NHL Market - Global Drivers and Barriers, 2017-2027
- Table 19: Key Historical and Projected Launch Dates for B-cell NHL
- Table 20: Key Historical and Projected Patent Expiry Dates for B-cell NHL
- Table 21: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
- List of Figures
- Figure 1: Global Sales Forecast by Region for B-Cell NHL in 2017 and 2027
- Figure 2: Competitive Assessment of the Marketed and Pipeline Drugs for iNHL (FL and MZL) Benchmarked Against the SOC, Rituxan (+/- chemotherapy)
- Figure 3: Competitive Assessment of the Marketed and Pipeline Drugs for DLBCL Benchmarked Against the SOC, Rituxan (+/- chemotherapy)
- Figure 4: Competitive Assessment of the Marketed and Pipeline Drugs for MCL Benchmarked Against the SOC, Rituxan (+/- chemotherapy)
- Figure 5: 7MM, Age-Standardized Diagnosed Incidence of B-Cell NHL, Ages ≥18 Years, 2017
- Figure 6: 7MM, Age-Standardized Diagnosed Prevalence of B-Cell NHL, Ages ≥18 Years, 2017
- Figure 7: Sources Used for Diagnosed Incident Cases of B-Cell NHL
- Figure 8: Sources Used for Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL
- Figure 9: Sources Used for Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL by Cancer Staging
- Figure 10: Sources Used for Diagnosed Incident Cases of FL by Grade
- Figure 11: Sources Used for Diagnosed Prevalent Cases of B-Cell NHL
- Figure 12: Sources Used for Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL
- Figure 13: 7MM, Diagnosed Incident Cases of B-Cell NHL, Men and Women, Ages ≥18 Years, 2017
- Figure 14: 7MM, Age-Specific Diagnosed Incident Cases of B-Cell NHL, Men and Women, 2017
- Figure 15: 7MM, Sex-Specific Diagnosed Incident Cases of B-Cell NHL, Men and Women, Ages ≥18 Years, 2017
- Figure 16: 7MM, Diagnosed Incident Cases of DLBCL, FL, MZL, and MCL, Men and Women, Ages ≥18 Years, 2017
- Figure 17: 7MM, Diagnosed Incident Cases of DLBCL by Cancer Stage, Men and Women, Ages ≥18 Years, 2017
- Figure 18: 7MM, Diagnosed Incident Cases of FL by Cancer Stage, Men and Women, Ages ≥18 Years, 2017
- Figure 19: 7MM, Diagnosed Incident Cases of MZL by Cancer Stage, Men and Women, Ages ≥18 Years, 2017
- Figure 20: 7MM, Diagnosed Incident Cases of MCL by Cancer Stage, Men and Women, Ages ≥18 Years, 2017
- Figure 21: 7MM, Diagnosed Incident Cases of FL by Grade, Men and Women, Ages ≥18 Years, 2017
- Figure 22: 7MM, Diagnosed Prevalent Cases of B-Cell NHL, Men and Women, ≥18 Years, 2017
- Figure 23: 7MM, Diagnosed Prevalent Cases of DLBCL, FL, MZL, and MCL, Men and Women, Ages ≥18 Years, 2017
- Figure 24: Unmet Needs and Opportunities in B-cell NHL
- Figure 25: Overview of the Development Pipeline in iNHL (FL and MZL)
- Figure 26: Overview of the Development Pipeline in DLBCL
- Figure 27: Overview of the Development Pipeline in MCL
- Figure 28: Key Phase II/III Trials for the Pipeline Agents in the 7MM During the Forecast Period
- Figure 29: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, iNHL
- Figure 30: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Indolent DLBCL
- Figure 31: Competitive Assessment of the Marketed and Pipeline Drugs Benchmarked Against the SOC, Indolent MCL
- Figure 32: Global (7MM) Sales Forecast by Region for B-cell NHL in 2017 and 2027
- Figure 33: Global (7MM) Sales Forecast by Class for Disease B-cell NHL in 2017 and 2027
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook